News und Analysen
3 Things You Can Expect in Gilead Sciences' Q2 Update
When Gilead Sciences (NASDAQ: GILD) reported its first-quarter results in May, expectations were low. The biotech didn't surprise anyone with dramatically lower revenue and earnings than the
3 Things You Can Expect in Gilead Sciences' Q2 Update
When Gilead Sciences (NASDAQ: GILD) reported its first-quarter results in May, expectations were low. The biotech didn't surprise anyone with dramatically lower revenue and earnings than the
Why ImmunoGen, Inc. Jumped Higher Today
ImmunoGen (NASDAQ: IMGN) closed up 12% today on no apparent good news. In fact, there was a bit of bad news on Friday after partner Bayer revealed that anetumab ravtansine, which ImmunoGen helped
Better Buy: Johnson & Johnson vs. AbbVie
It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. The two healthcare stocks are up by nearly identical levels year to date. And that's
Better Buy: Johnson & Johnson vs. AbbVie
It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. The two healthcare stocks are up by nearly identical levels year to date. And that's
5 Things You Probably Didn't Know About Pfizer Inc.
Many people can name one of Pfizer's (NYSE: PFE) products. From over-the-counter products such as Advil and Robitussin to powerful prescription drugs such as Eliquis and Ibrance, Pfizer makes some of
5 Things You Probably Didn't Know About Pfizer Inc.
Many people can name one of Pfizer's (NYSE: PFE) products. From over-the-counter products such as Advil and Robitussin to powerful prescription drugs such as Eliquis and Ibrance, Pfizer makes some of
3 Beaten-Up Biotechs Bouncing Back in 2017 (Hint: One Is a Marijuana Stock)
Not every stock that falls on tough times is worth buying in portfolios, but sometimes, catalysts can spark shareholder-friendly rallies, and in those situations, it can make sense. For example
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
$45 billion for five experimental drugs.That's how much market research firm EvaluatePharma projects the five most valuable pipeline candidates are worth right now. The firm calculated the net present
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
$45 billion for five experimental drugs.That's how much market research firm EvaluatePharma projects the five most valuable pipeline candidates are worth right now. The firm calculated the net present
Should Investors Brace for Bad News From Novavax's Looming Clinical Update?
One press release last week caused shares of clinical-stage biotech Novavax (NASDAQ: NVAX) to soar nearly 25%. The company didn't announce an FDA approval. It didn't even report results from a
Better Buy: Celgene Corporation vs. Gilead Sciences, Inc.
Celgene (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) are two big biotechs facing dramatically different outlooks for the future. Their stock prices reflect that reality. Celgene's share price is
Better Buy: Celgene Corporation vs. Gilead Sciences, Inc.
Celgene (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) are two big biotechs facing dramatically different outlooks for the future. Their stock prices reflect that reality. Celgene's share price is
Better Buy: Celgene Corporation vs. Gilead Sciences, Inc.
Celgene (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) are two big biotechs facing dramatically different outlooks for the future. Their stock prices reflect that reality. Celgene's share price is
Better Buy: AbbVie Inc. vs. Johnson & Johnson
U.S.-based pharmaceutical companies are enjoying a much friendlier business environment under President Trump than his predecessor. President Trump, after all, has backed away from the repeated calls
Better Buy: AbbVie Inc. vs. Johnson & Johnson
U.S.-based pharmaceutical companies are enjoying a much friendlier business environment under President Trump than his predecessor. President Trump, after all, has backed away from the repeated calls
Here's How to Find the Best Dividend Stocks
Finding great income stocks would be easy if the only metric that mattered was yield. If that was true, then an investor would simply screen for the highest-yielding stocks they could find and buy
Here's How to Find the Best Dividend Stocks
Finding great income stocks would be easy if the only metric that mattered was yield. If that was true, then an investor would simply screen for the highest-yielding stocks they could find and buy
It Took Just 10 Days for Nevada's Recreational Marijuana Industry to Fall Into a State of Emergency
When discussing the fastest-growing industries on the planet, few, or none, may top the legal marijuana industry. According to cannabis research group ArcView, North American legal pot sales are
3 Been-There-Done-That Biotech CEOs Who Are Doing it Again
You might want to turn back the clock so that you can profit from Puma Biotechnology's (NASDAQ: PBYI) 212% return this year, but unfortunately, you can't. Instead, you'll just have to go out and find
2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't
Exelixis (NASDAQ: EXEL) is without question one of the hottest biotech stocks on the market. We're talking about a stock that has more than tripled in value in just the last 12 months and has soared
Intuitive Surgical, Inc. Slow Earnings Growth Masks Deeper Strength
One look at the bottom line from Intuitive Surgical's (NASDAQ: ISRG) earnings release and you might think that the company had hit a speed bump. With the stock trading at 42 times trailing (non-GAAP)
Intuitive Surgical, Inc. Slow Earnings Growth Masks Deeper Strength
One look at the bottom line from Intuitive Surgical's (NASDAQ: ISRG) earnings release and you might think that the company had hit a speed bump. With the stock trading at 42 times trailing (non-GAAP)
Intuitive Surgical, Inc. Slow Earnings Growth Masks Deeper Strength
One look at the bottom line from Intuitive Surgical's (NASDAQ: ISRG) earnings release and you might think that the company had hit a speed bump. With the stock trading at 42 times trailing (non-GAAP)
3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now?
Biotechnology's top performing stocks this year have already given investors envy-inspiring returns, but there's reason to believe that Calithera Biosciences (NASDAQ: CALA), Aurinia Pharmaceuticals